NIA’s ITP Confirms: Resveratrol Does Not Extend Lifespan; Limited Benefit to Rapamycin
SENS (Strategies for Engineered Negligible Senescence) reserachers reviewed the results of the serendipitous late-life lifespan study of rapamycin (sirolimus/Rapamune®), an inhibitor of the mammalian Target of Rapamycin (mTOR) pathway, through the NIA’s Interventions Testing Program (ITP), “a multi-institutional study investigating treatments with the potential to extend lifespan and delay disease and dysfunction in mice.” This …